Page 65 - Biomarkers for risk stratification and guidance in heart failure
P. 65
Chapter 3
14. Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: A report from the euro heart survey on heart failure. European heart journal. 2005;26:2706-2713
15. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. American heart journal. 1999;138:1126-1132
16. Yoshimura M, Mizuno Y, Nakayama M, Sakamoto T, Sugiyama S, Kawano H, Soejima H, Hirai N, Saito Y, Nakao K, Yasue H, Ogawa H. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. The American journal of medicine. 2002;112:716-720
17. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. Journal of the American College of Cardiology. 2002;39:1615-1622
18. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L, EuroHeart Survey I, Heart Failure Association ESoC. Euroheart failure survey ii (ehfs ii): A survey on hospitalized acute heart failure patients: Description of population. European heart journal. 2006;27:2725-2736
19. Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, Ordonez-Llanos J, Valdes M, Cinca J. Serial nt-probnp monitoring and outcomes in outpatients with decompensation of heart failure. International journal of cardiology. 2007;120:338-343
20. O’Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge, but not admission, levels of nt- probnp predict adverse prognosis following acute lvf. European journal of heart failure. 2003;5:499-506
64
